Cytosorbents (CTSO) stock price, revenue, and financials

Cytosorbents market cap is $207.7 m, and annual revenue was $15.15 m in FY 2017

$207.7 M

CTSO Mkt cap, 10-Jun-2019

$15.2 M

Cytosorbents Revenue FY, 2017
Cytosorbents Revenue growth (FY, 2016 - FY, 2017), %59%
Cytosorbents Gross profit (FY, 2017)9.6 M
Cytosorbents Gross profit margin (FY, 2017), %63.6%
Cytosorbents Net income (FY, 2017)-8.5 M
Cytosorbents EBIT (FY, 2017)-9.8 M
Cytosorbents Cash, 31-Dec-201717.3 M
Cytosorbents EV200.4 M

Cytosorbents Revenue

Cytosorbents revenue was $15.15 m in FY, 2017 which is a 59% year over year increase from the previous period.

Embed Graph

Cytosorbents Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017

Revenue

4.8m9.5m15.2m

Revenue growth, %

99%59%

Cost of goods sold

2.2m4.0m5.5m

Gross profit

2.6m5.6m9.6m

Gross profit Margin, %

54%59%64%

R&D expense

3.9m4.8m4.0m

General and administrative expense

6.9m11.1m14.1m

Operating expense total

11.9m17.1m19.5m

EBIT

(9.3m)(11.5m)(9.8m)

EBIT margin, %

(194%)(121%)(65%)

Interest expense

231.8k749.1k

Interest income

9.3k

Pre tax profit

(8.5m)(12.1m)(9.1m)

Income tax expense

(324.6k)(318.5k)(676.7k)

Net Income

(8.1m)(11.8m)(8.5m)

Cytosorbents Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017

Cash

5.3m5.2m17.3m

Accounts Receivable

648.9k1.4m2.2m

Prepaid Expenses

511.9k315.8k416.0k

Inventories

1.2m834.0k795.7k

Current Assets

9.9m7.8m20.7m

PP&E

557.3k569.4k1.4m

Total Assets

11.3m9.7m24.1m

Accounts Payable

684.6k1.3m1.2m

Short-term debt

833.3k4.0m

Current Liabilities

3.0m4.3m7.8m

Long-term debt

4.1m6.0m

Non-Current Liabilities

4.1m6.0m

Total Debt

4.9m10.0m

Total Liabilities

3.0m8.4m13.8m

Common Stock

25.4k25.5k29.0k

Additional Paid-in Capital

140.1m143.9m162.9m

Retained Earnings

(132.5m)(143.5m)(152.3m)

Total Equity

8.2m1.3m10.3m

EPS

(0.3)(0.5)(0.3)

Debt to Equity Ratio

3.7 x1 x

Debt to Assets Ratio

0.5 x0.4 x

Financial Leverage

1.4 x7.2 x2.3 x

Cytosorbents Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017

Net Income

(8.1m)(11.8m)(8.5m)

Depreciation and Amortization

113.0k161.6k218.3k

Accounts Receivable

132.0k(889.7k)(649.3k)

Inventories

(671.3k)340.4k57.3k

Accounts Payable

(83.2k)2.1m523.4k

Cash From Operating Activities

(9.0m)(6.7m)(6.5m)

Purchases of PP&E

(403.6k)(140.7k)(990.7k)

Cash From Investing Activities

(890.9k)1.6m(1.7m)

Long-term Borrowings

(118.8k)(1.6k)

Cash From Financing Activities

11.6m5.1m20.1m

Net Change in Cash

1.7m(71.7k)12.1m

Interest Paid

175.9k634.6k

Cytosorbents Ratios

USDY, 2017

EV/EBIT

-17.5 x

EV/CFO

-26.6 x

Revenue/Employee

233.1k

Debt/Equity

1 x

Debt/Assets

0.4 x

Financial Leverage

2.3 x

P/E Ratio

(17.3)